Furthermore, another multi-center, open label, phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT for patients with TP53 mutant AML or MDS is also ongoing (NCT03931291) (Table 2). Here, TP53 is linked to myelodysplastic syndrome.